Survey of oncologists finds knowledge gap on medical marijuana
As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers.
Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial oncology at the Dana-Farber Cancer Institute, led a survey of cancer physicians around the country, exploring their attitudes and actions on medical marijuana.
The survey was sent to 400 oncologists, with a 63 percent response rate. We asked Braun to outline her findings, which were published last month in the Journal of Clinical Oncology.
Stories you may be interested in
Cannabis and Mental Health: Social Anxiety Disorder
Social anxiety may sound like something we all experience at times in life, and that is true. It is natural for a person to feel nervous or anxious in situations like being alone in a new place or going on a first date. But for those living with social anxiety disorder, those instances of anxiety…
Read More 
After 50 Years, U.S. Opens The Door To More Cannabis Crops For Scientists
After more than 50 years, the federal government is lifting a roadblock to cannabis research that scientists and advocates say has hindered rigorous studies of the plant and possible drug development. Since 1968, U.S. researchers have been allowed to use cannabis from only one domestic source: a facility based at the University of Mississippi, through a…
Read More 
Texas House Bill 3703: What You Need to Know
The state of Texas has been in the news in recent months as the legislature review House Bill 3703. This bill relates to “the prescription of low-THC cannabis for medical use by certain qualified physicians to patients with [specific] qualifying conditions”. Originally filed in March of 2019, this bill made its way through the house…
Read More 
Dr. Sanjay Gupta on medical marijuana: We are in an age of wisdom, but also an age of foolishness
When we released “Weed” in 2013, few people had ever heard of cannabidiol, or CBD. Now, two-thirds of Americans are familiar with the compound, and 1 in 7 have tried it. Most of the country, 93%, are in favor of medical marijuana and hemp-derived CBD itself, which has less than 0.3% THC, has been legalized in every state.It’s…
Read More 
Aching for a Better Alternative?
To close out Arthritis Awareness Month, we’re highlighting how medical marijuana may be a beneficial alternative treatment for this painful and debilitating disease. With over 31 million Americans suffering from various types of arthritis, the condition stands as the leading disability throughout the U.S. As many may know, arthritis is most common among the middle-aged…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More